SCHEMBL14474183

SCHEMBL14474183

CNc1nc(-c2cnccn2)nc2c(OC)cc(-c3ccc(F)cc3)cc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KIT P10721 1/20 0.39
▸ MAP3K11 Q16584 2/20 0.39
▸ PDGFRB P09619 1/20 0.38
▸ PDGFRA P16234 1/20 0.38
▸ TDO2 P48775 2/20 0.38
▸ IDO1 P14902 1/20 0.38
▸ KDM4E B2RXH2 2/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ LMNA P02545 2/20 0.37
▸ CYP1A2 P05177 2/20 0.37
▸ CYP3A4 P08684 2/20 0.37
▸ CYP2D6 P10635 2/20 0.37
▸ MAPK1 P28482 2/20 0.37
▸ CYP2C19 P33261 2/20 0.37
▸ HSD17B10 Q99714 2/20 0.37
▸ TDP1 Q9NUW8 2/20 0.37
▸ TSHR P16473 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ HPGD P15428 1/20 0.36
▸ AAK1 Q2M2I8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14474187 0.93 SCN9A (0.38) KITMAP3K11TDO2IDO1KDM4E
SCHEMBL16184204 0.92 SYK (0.43) KITPDGFRBPDGFRATDO2IDO1
SCHEMBL16184213 0.92 KIT (0.38) KITPDGFRBPDGFRATDO2KDM4E
SCHEMBL16184191 0.91 PDGFRB (0.39) MAP3K11PDGFRBPDGFRAKDM4EALDH1A1
SCHEMBL16184202 0.91 NPC1 (0.41) KITKDM4EALDH1A1LMNACYP1A2
SCHEMBL16184203 0.91 CYP1A2 (0.42) KITKDM4EALDH1A1LMNACYP1A2
SCHEMBL16184183 0.90 KIT (0.41) KITPDGFRBPDGFRASCN9APDE2A
SCHEMBL14474202 0.90 CHRNA7 (0.45) KITMAP3K11LMNACYP2D6CYP2C19
SCHEMBL14358650 0.89 MAP3K11 (0.38) KITMAP3K11KDM4EALDH1A1LMNA
SCHEMBL16184198 0.89 TGFBR1 (0.38) KITMAP3K11KDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
WO-2013003586-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB KIT 3161/4885MAP3K11 914/4885PDGFRB 2489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback